1. Fig. 2. Clinically actionable somatic genomic alterations in various tumor types.
Clinically actionable somatic genomic alterations in various tumor types. Each bar represents the fraction of cases with mutations in clinically actionable genes as determined by the comparison of alterations to genes that were associated with established FDA-approved therapies (brown), previously published clinical trials (green), or current clinical trials in the same tumor type (blue). For approved therapies and previously published clinical trials, potential actionability was also considered in tumor types that were different from those where the clinical use has been described (light brown and light green, respectively). Some of the colorectal tumors analyzed were from patients with tumors known to be KRAS wild type, resulting in a lower fraction of cases with actionable changes related to FDA-approved therapies.
Siân Jones et al., Sci Transl Med 2015;7:283ra53
Copyright © 2015, American Association for the Advancement of Science